Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a BetZacks Investment Research • 11/10/25
GH Research Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/06/25
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP CongressGlobeNewsWire • 10/09/25
GH Research Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 08/07/25
GH Research Announces Global Pivotal Program Plans and Further Development UpdatesGlobeNewsWire • 07/23/25
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to TradeZacks Investment Research • 07/16/25
FDA seen likely to grant emergency use authorizations for psychedelics, boosting sector stocksProactive Investors • 06/18/25
GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual MeetingGlobeNewsWire • 05/15/25
GH Research Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/08/25
GH Research Reports Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 02/27/25
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS ReductionGlobeNewsWire • 02/03/25
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-RodentsGlobeNewsWire • 01/10/25
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?Zacks Investment Research • 11/20/24
GH Research Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 11/14/24
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)Zacks Investment Research • 09/09/24